Market Overview

The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings
Related IBB
The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist
Drug Companies To Disclose Pricing Information In Ads
FDA issues new guidance aimed at more efficient drug development (Seeking Alpha)
Related ZFGN
The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial
The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 2)

  • Akcea Therapeutics Inc (NASDAQ: AKCA)
  • Arbutus Biopharma Corp (NASDAQ: ABUS)
  • AtriCure Inc. (NASDAQ: ATRC)
  • Cytosorbents Corp (NASDAQ: CTSO)
  • Eli Lilly And Co (NYSE: LLY)
  • Glaukos Corp (NYSE: GKOS)
  • Illumina, Inc. (NASDAQ: ILMN)
  • LivaNova PLC (NASDAQ: LIVN)
  • Masimo Corporation (NASDAQ: MASI)
  • Replimune Group Inc (NASDAQ: REPL)
  • Tandem Diabetes Care Inc (NASDAQ: TNDM)
  • Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
  • Zoetis Inc (NYSE: ZTS)

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 2)

  • Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)
  • Avenue Therapeutics Inc (NASDAQ: ATXI)
  • Bioblast Pharma Ltd (NASDAQ: ORPN)
  • Catabasis Pharmaceuticals Inc (NASDAQ: CATB)
  • Clovis Oncology Inc (NASDAQ: CLVS)
  • Constellation Pharmaceuticals Inc (NASDAQ: CNST)
  • Cue Biopharma Inc (NASDAQ: CUE)
  • Epizyme Inc (NASDAQ: EPZM)
  • Flex Pharma Inc (NASDAQ: FLKS)
  • Fortress Biotech (NASDAQ: FBIO)
  • IntelliPharmaCeutics Intl Inc (USA) (NASDAQ: IPCI)
  • Midatech Pharma PLC-ADR (NASDAQ: MTP)
  • Radius Health Inc (NASDAQ: RDUS)
  • Vascular Biogenics Ltd (NASDAQ: VBLT)
  • Verrica Pharmaceuticals Inc (NASDAQ: VRCA)

Stocks In Focus

Zafgen's Chief Scientific Officer Quits

Zafgen Inc (NASDAQ: ZFGN) said its President and chief scientific officer Thomas Hughes has resigned from the role to take up the CEO position at a privately-held biotech company.

The stock fell 5.69 percent to $9.78 in after-hours trading.

Stocks Reacting to Earnings

TESARO Inc (NASDAQ: TSRO) – plunged 12.45 percent to $31 (reported a loss of $3.04 per share and revenues of $53.89 million, missing the consensus estimates for a loss of $2.65 per share and revenues of $63.34 million)

Acceleron Pharma Inc (NASDAQ: XLRN) – rallied 9.96 percent to $48.02 (reported a Q2 loss of 63 cents, narrower than the 64 cents per share last year)

Adamas Pharmaceuticals Inc (NASDAQ: ADMS) – jumped 13.32 percent to $28.25 (reported a loss of $1.26 compared to the loss of $1.41 per share estimated by analyst; revenues of $7.57 million also trumped the consensus estimate of $4.86 million.

T2 Biosystems Inc (NASDAQ: TTOO) – climbed 9.93 percent to $6.20 (reported Q2 revenues of $3.9 million and an in-line loss of 32 cents per share; The company reiterated its expectations for the full year.)

Pacific Biosciences of California (NASDAQ: PACB) – slumped 9.02 percent to $3.53 (reported below-consensus revenues for Q2 and an in-line loss)

CytoSorbents – rallied 8.14 percent to $13.95 (reported Q2 revenues of $5.8 million, up 61 percent year-over-year and exceeding the consensus estimate; loss was 19 cents per share compared to the year-ago loss of 6 cents per share.)

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) – rose 2.47 percent to $2.90 (reported a narrower loss of 18 cents per share compared to the consensus expectations for a loss of 37 cents per share; Revenues climbed to $11.6 million, also coming in ahead of the $2.19 million consensus estimate.)

Aratana Therapeutics Inc (NASDAQ: PETX) – rose 3.79 percent to $4.66 (reported a loss of 14 cents per share on revenues of $4.9 million for Q2; Analysts, on average, estimated a loss of 19 cents per share on revenues of $5.06 million.)

Genomic Health, Inc. (NASDAQ: GHDX) – gained 2.19 percent to $55.50 (reported Q2 EPS of 23 cents, sharply higher than the 6 cents per share estimated by analysts; revenues of $95.6 million also beat the $92.11 million consensus estimate.)

Posted-In: Biotech Earnings News Trading Ideas


Related Articles (ABUS + ACRS)

View Comments and Join the Discussion!

30 Stocks Moving In Friday's Pre-Market Session

The Cannabis Industry's Go-Public Frenzy: A Chat With Companies That IPOed This Year